About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical ...

In the AMPLIFY study, fixed-duration venetoclax-acalabrutinib reduced the risk of disease progression or death by 35% compared with chemoimmuntherapy.

Medical experts provide an overview of chronic lymphocytic leukemia (CLL), including its typical symptoms and diagnostic process. They also will inquire about key prognostic factors and their impact ...

The discussion will wrap up with perspectives on the future of CLL treatment, including anticipated improvements in patient care and quality of life, emerging therapies, and evolving patient roles in ...

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows ...

AstraZeneca’s CALQUENCE® (acalabrutinib) in combination with venetoclax has been approved in the US as the first all-oral, fixed-duration regimen for the treatment of adult patients with chronic ...

Medical experts provide their final thoughts regarding key treatment considerations for CLL and SLL. This is a video synopsis/summary of a Peer Exchange involving: Ryan Haumschild, PharmD, MS, MBA, ...

Novel targeted therapies for R/R CLL, including venetoclax plus rituximab, acalabrutinib, and zanubrutinib, have favorable safety profiles. Bendamustine plus rituximab showed a lower risk of severe ...

MILAN — Is chronic lymphocytic leukemia (CLL) progression primarily driven by genetic mutations or by external cues from the tumor microenvironment? Despite major strides in targeted therapies, CLL ...

Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of oncologic, ...

The US Food and Drug Administration (FDA) has granted accelerated approval to pirtobrutinib (Jaypirca; Eli Lilly and Company) for third-line or later treatment in adults with chronic lymphocytic ...

People with chronic lymphocytic leukemia (CLL) may be at higher risk of severe illness from COVID-19. While the COVID-19 vaccines may not be as effective in these individuals, health experts still ...